BCL2 and non-Hodgkin lymphoma: Levels of Bcl-2 family members have been reported to predict response to venetoclax in AML and MM [49, 50], while Bcl-2 expression did not correlate with overall response rate to venetoclax in a phase I study in non-Hodgkin lymphoma [51].